A minoglycoside antibiotics -which bind to prokaryotic ribosomal RNA to inhibit protein synthesishave been used since the 1940s to treat bacterial infections 1 . At present, tobramycin, gentamicin, amikacin, streptomycin, neomycin and paromomycin are approved for use in patients. However, aminoglycosides have other activities in addition to their antibacterial properties 2 . For example, some aminoglycosides bind to human ribosomal mRNA, which can result in read-through of premature stop codons, and have been used in clinical trials for treatment of genetic disorders. Aminoglycosides also bind to other RNAs, including ribozymes, resulting in inhibition of the latter's activity, and to the transactivation response (TAR) element in HIV, resulting in dissociation of the HIV Tat protein from the viral genome. Gopinath et al. 3 report in this issue of Nature Microbiology that certain aminoglycosides can inhibit virus replication in cell culture, and that prophylactic application of these antibiotics to mucosal surfaces in mice can reduce virus replication. They show that this effect is not mediated through their action on the microbiota of the animal, since similar effects are seen in germ-free mice. Rather, aminoglycosides induce the mucosal recruitment and expression of interferon (IFN)-stimulated genes (ISGs) in dendritic cells in a Tolllike receptor 3 (TLR3)-dependent manner, which probably accounts for their antiviral activity. Certain aminoglycosides, including neomycin and kanamycin, induced ISGs, while others such as streptomycin and amikacin did not. Importantly, only aminoglycosides that induced ISGs protected mice from challenge with herpes simplex virus (HSV). Topical administration of certain aminoglycosides can also prolong survival in mice after intranasal challenge with influenza and reduce shedding after intravaginal challenge with Zika virus.
IFNs are critical components of the host response to virus infection (Fig. 1) . They induce the expression of hundreds of ISGs that inhibit virus replication 4 through sequences in ISG promoters termed IFN-stimulated response elements (ISREs). Using a high-throughput screen of over 2,000 drugs, Patel et al. identified 64 compounds that activate ISREs 5 . These included 4 antibiotics, 11 cardiovascular drugs and 6 anti-neoplastic drugs. Several anthracyclines approved for cancer therapy, including daunorubicin, doxorubicin and idarubicin, activated ISREs; idarubicin was found to increase expression of several ISGs and inhibit replication of encephalomyocarditis virus in vitro, without inducing cytotoxicity. A subsequent study by these authors showed that several statins activated ISREs, increased expression of ISGs when expressed with IFNβ , and inhibited replication of human rhinovirus and respiratory syncytial virus in vitro 6 . Thus, it seems that various drugs can activate ISREs and inhibit virus replication. Unlike these prior in vitro studies, however, Gopinath et al. 3 showed a broad effect of certain aminoglycosides against both RNA and DNA viruses in animal models.
Gopinath et al. 3 found that induction of ISGs by neomycin was due, at least in part, to activation of the TLR3 pathway and dependent on signalling by TRIF and IFN regulatory factor (IRF) 3/7. TLR3, along with TLR7, 8 and 9, is located in endosomes (Fig. 1) . Activation of TLR3 by doubled-stranded RNA induces a signalling pathway that leads to synthesis of IFN and ultimately production of ISGs in neighbouring cells to protect them from virus infection. Aminoglycosides are known to bind to host cell RNA, which might trigger TLR3 activation, but this has not been established. Several TLR3 and TLR9 agonists are used as vaccine adjuvants and they enhance immune responses, including production of IFN and ISGs
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. For example, CpG is a TLR9 agonist recently approved as an adjuvant for a hepatitis B vaccine. Poly I:C is a TLR3 agonist and an investigational adjuvant for vaccines, particularly for cancer. Like aminoglycosides, poly I:C has been reported to inhibit replication of several viruses, including HSV and influenza. Thus, aminoglycosides are TLR3-dependent activators of ISGs and may have potential as adjuvants.
Gopinath et al. 3 report that prophylactic application of aminoglycosides to the nasal or vaginal mucosa of mice protected the animals from infection with certain DNA or RNA viruses, although the effects were transient. Prophylactic treatment of mice with intravaginal neomycin prior to genital challenge with HSV reduced disease; however, vaginal shedding, a key endpoint in the mouse HSV infection model, was only inhibited during the first three days of infection and then reached levels similar to those in untreated mice.
Pretreatment of mice congenic for Mx1, an ISG that is critical for protection of animals from influenza, with intranasal neomycin significantly improved survival; however, about 50% of the mice died. Pretreatment of mice with intravaginal neomycin or kasugamycin reduced the levels of Zika virus RNA in vaginal mucosa for the first two days after challenge, but after the third day the effect was no longer significant in the neomycin-treated animals. Thus, while prophylactic use of certain aminoglycosides significantly improved outcomes in animals, the effects were modest.
Might aminoglycosides, or their derivatives, be useful for inhibiting virus infections at mucosal surfaces in humans? As noted above, aminoglycosides were found to induce ISGs, resulting in an antiviral state, but only when used for several days before infection with virus. When initiated 24 hours after infection of mice with HSV, at a time when animals were still asymptomatic, aminoglycosides had a variable effect on disease. Imiquimod, a TLR7 agonist, induces production of IFNα and tumour necrosis factor-α and is approved for topical treatment of preexisting human papillomavirus infections, and is used off-label as topical therapy for acyclovir-resistant HSV 8 . It is, therefore, likely that topical aminoglycosides, which also work through the IFN pathway, would be less effective than topical imiquimod. However, while imiquimod may induce an inflammatory response that limits its use, topical aminoglycosides might be better tolerated. Nevertheless, as the authors note, topical administration of aminoglycosides would alter the microbiome and this may increase the risk of outgrowth of pathogenic bacteria. Thus, while current aminoglycosides seem unlikely to be clinically useful to prevent virus infections, derivatives of these drugs might be more effective and have less effects on the microbiome. The work of Gopinath et al. 3 provides yet another activity for an old class of drugs, and suggests that in addition to altering the bacterial microbiome, treatment of patients with aminoglycosides might also alter their virome through the induction of ISGs. ❐ Jeffrey I. Cohen
